A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

S. Cascinu, L. Frontini, R. Labianca, V. Catalano, S. Barni, C. Graiff, G. Picone, F. Farinati, S. Zonato, M. A. Pessi, C. Curti, G. Catalano

Research output: Contribution to journalArticle

Abstract

Background: Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m2/min may be more effective than the standard 30-min infusion of Gemcitabine (GEM). Patients and methods: Thirty-four patients with histologically verified locally unresectable and/or metastatic pancreatic carcinoma received GEM at the dose of 1,500 mg/m2 with an infusion rate of 10 mg/m2/min, associated to 5-fluorouracil (5-FU) at the dose of 600 mg/m2. Both drugs were administered weekly for two consecutive weeks out of every three weeks. Results: One complete and five partial responses have been observed for an overall response rate of 17% (95% CI: 3%-27%). The time to progression was 3.7 months with a median survival of 5.7 months. A clinical benefit was obtained in 5 of 29 patients (17%). Grade 3-4 WHO toxicities included neutropenia (35%) and thrombocytopenia (10%). Conclusion: It is unlikely that a fixed dose rate infusion of GEM, at least with this dose, can improve palliation in comparison with the standard 30-min infusion schedule in advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)1309-1311
Number of pages3
JournalAnnals of Oncology
Volume11
Issue number10
DOIs
Publication statusPublished - 2000

Keywords

  • Gemcitabine
  • Infusion schedule
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)'. Together they form a unique fingerprint.

  • Cite this

    Cascinu, S., Frontini, L., Labianca, R., Catalano, V., Barni, S., Graiff, C., Picone, G., Farinati, F., Zonato, S., Pessi, M. A., Curti, C., & Catalano, G. (2000). A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 11(10), 1309-1311. https://doi.org/10.1023/A:1008393010472